Novartis said the drug’s so-called multi-specific protein-based domains ensure strong neutralization of the CCP virus, even in the face of mutations of the pathogen’s spike protein, while limiting the development of escape mutants.
Novartis said the drug’s so-called multi-specific protein-based domains ensure strong neutralization of the CCP virus, even in the face of mutations of the pathogen’s spike protein, while limiting the development of escape mutants.